Scribe Therapeutics Inc.
NASDAQScribe Therapeutics enters September in a peculiar position — the stock has shed 7% on the week and 5% in a single session, yet four analyst initiations and a cluster of insider buying tell a sharply different story about where sentiment is heading. The analyst angle here is the lead. Four firms kicked off coverage within the past two weeks, all with bullish ratings. HC Wainwright…
SCTX short interest plummets 24.6% in one week to 299,127 shares, with cost to borrow easing to 26.6% from recent highs above 40%.
Snapshot as of 3 Sept 2026
Scribe Therapeutics enters September in a peculiar position — the stock has shed 7% on the week and 5% in a single session, yet four analyst initiations and a cluster of insider buying tell a sharply different story…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for SCTX — free to start on ORTEX.
Sign up for free →Open SCTX on ORTEXPulses are triggered by ORTEX's live data feeds. The full signal history, thresholds, and alerts are on ORTEX.
Live SCTX data →